On July 14, 2020 Acepodia, a biotechnology company developing cancer immunotherapies based on its novel Antibody-Cell Conjugation (ACC) technology platform and JW Therapeutics, a biotechnology company focusing on the development, transformation and promotion of cell immunotherapy, have reported a collaboration to develop and commercialize ACE1702 and ACE1655, two of Acepodia’s cell therapy candidates for the treatment of solid tumors and hematologic malignancies, respectively, in Mainland China, Hong Kong, and Macau (Press release, Acepodia, JUL 14, 2020, View Source [SID1234616138]). Acepodia will receive upfront and milestone payments in addition to royalties on sales
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
Acepodia’s allogeneic cell therapy platform is based on optimizing its proprietary, potent and off-the-shelf natural killer cell line (oNK cells) with tumor-targeting mechanisms through its antibody-cell conjugation (ACC) technology that links antibodies directly to the surface proteins of immune cells to enhance their tumor-killing ability.
"We are excited to partner with Acepodia to advance NK cell-based therapies through the clinic, with the goal of eventually introducing these innovative therapies to patients. Acepodia has applied a broad and integrative approach to providing more potential clinical treatment options for solid tumors and hematologic malignancies, with the ability to scale up production of these targeted cell-therapies, as needed," said James Li, M.D., chief executive officer of JW Therapeutics.
Sonny Hsiao, Ph.D., chief executive officer of Acepodia added, "This partnership perfectly captures the synergies between Acepodia and JW Therapeutics. By combining our research capabilities and novel cell therapy platform with JW Therapeutics’ translational cancer immunology research and development capacity, this collaboration is aptly suited to develop and commercialize our oNK cell therapies in these regional markets. We look forward to working with JW Therapeutics to advance these therapies through the clinic, maximizing their allogeneic and ‘off-the-shelf’ treatment potential."